Cytokinetics Historical Income Statement
| CYTK Stock | USD 50.25 1.15 2.34% |
Historical analysis of Cytokinetics income statement accounts such as Other Operating Expenses of 528.9 M, Research Development of 334.1 M or Total Operating Expenses of 182.3 M can show how well Cytokinetics performed in making a profits. Evaluating Cytokinetics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cytokinetics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cytokinetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cytokinetics is a good buy for the upcoming year.
Cytokinetics |
About Cytokinetics Income Statement Analysis
Cytokinetics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cytokinetics shareholders. The income statement also shows Cytokinetics investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cytokinetics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cytokinetics. It is also known as Cytokinetics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Cytokinetics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cytokinetics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.At this time, Cytokinetics' Depreciation And Amortization is quite stable compared to the past year. Cost Of Revenue is expected to rise to about 346.6 M this year, although the value of EBITDA is projected to rise to (433.8 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 256.7M | 418.8M | 503.7M | 528.9M | Interest Expense | 29.3M | 51.2M | 57.7M | 60.6M |
Cytokinetics income statement Correlations
Click cells to compare fundamentals
Cytokinetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cytokinetics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 27.4M | 38.7M | 29.3M | 51.2M | 57.7M | 60.6M | |
| Other Operating Expenses | 125.7M | 149.8M | 256.7M | 418.8M | 503.7M | 528.9M | |
| Operating Income | (98.9M) | (93.9M) | (186.3M) | (324.2M) | (496.2M) | (471.4M) | |
| Ebit | (98.9M) | (88.6M) | (186.0M) | (337.8M) | (468.6M) | (445.1M) | |
| Research Development | 86.1M | 97.0M | 159.9M | 6.6M | 318.2M | 334.1M | |
| Ebitda | (93.0M) | (86.8M) | (176.3M) | (329.4M) | (456.7M) | (433.8M) | |
| Total Operating Expenses | 39.6M | 52.8M | 96.8M | 178.0M | 173.6M | 182.3M | |
| Net Income | (149.1M) | (164.1M) | (242.4M) | (402.6M) | (526.2M) | (499.9M) | |
| Income Tax Expense | 27.4M | 36.8M | 27.1M | 13.6M | 11.7M | 8.0M | |
| Selling General Administrative | 39.6M | 52.8M | 96.8M | 178.0M | 173.6M | 182.3M | |
| Total Revenue | 26.9M | 55.8M | 70.4M | 94.6M | 7.5M | 7.2M | |
| Gross Profit | (59.3M) | (41.1M) | (89.5M) | (146.2M) | (322.6M) | (306.5M) | |
| Depreciation And Amortization | 5.8M | 1.8M | 9.6M | 8.4M | 11.9M | 12.5M | |
| Cost Of Revenue | 86.1M | 97.0M | 159.9M | 240.8M | 330.1M | 346.6M | |
| Income Before Tax | (121.7M) | (127.3M) | (215.3M) | (389.0M) | (526.2M) | (499.9M) | |
| Total Other Income Expense Net | (22.8M) | (33.3M) | (29.0M) | (64.8M) | (30.0M) | (28.5M) | |
| Net Income Applicable To Common Shares | (121.7M) | (127.3M) | (215.3M) | (389.0M) | (350.1M) | (332.6M) | |
| Net Income From Continuing Ops | (101.0M) | (104.6M) | (202.4M) | (332.3M) | (526.7M) | (500.4M) | |
| Non Operating Income Net Other | 4.5M | 5.3M | 331K | 11.3M | 13.0M | 13.7M | |
| Interest Income | 4.5M | 5.3M | 331K | 11.3M | 26.0M | 27.3M | |
| Net Interest Income | (22.8M) | (33.3M) | (29.0M) | (39.8M) | (30.9M) | (32.5M) | |
| Reconciled Depreciation | 1.3M | 1.8M | 2.3M | 5.8M | 7.2M | 7.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.225 | Return On Assets (0.30) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.